Niagen Bioscience (NAGE) Cost of Revenue (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Cost of Revenue data on file, last reported at $3.5 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.5 million, down 68.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.6 million (up 40.54% YoY), and the FY2025 annual result was $46.2 million, up 56.89% from the prior year.
• Cost of Revenue slipped to $3.5 million in Q1 2026 per NAGE's latest filing, from $21.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $21.1 million in Q4 2025 and troughed at $1.9 million in Q4 2023.
• A 5-year average of $7.8 million and a median of $7.5 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue sank 73.24% in 2023, then jumped 786.09% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $7.1 million in 2022, then slumped by 73.24% to $1.9 million in 2023, then grew by 25.12% to $2.4 million in 2024, then jumped by 786.09% to $21.1 million in 2025, then sank by 83.36% to $3.5 million in 2026.
• Business Quant data shows NAGE's Cost of Revenue at $3.5 million in Q1 2026, $21.1 million in Q4 2025, and $8.8 million in Q3 2025.